{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-000155","form_type":"8-K","ticker":"BCRX","cik":"0000882796","company_name":"BIOCRYST PHARMACEUTICALS INC","filed_at":"2025-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.654952+00:00","generated_at":"2026-05-28T06:01:29.814937+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"BioCryst reports FY2024 ORLADEYO net revenue $437M (+34% YoY), guides FY2025 $515-535M","bullets":["Preliminary FY2024 ORLADEYO net revenue $437M (+34% YoY); Q4 net revenue $123.5M (+36% YoY).","Total FY2024 revenue $450M (+36% YoY); FY2025 total revenue guidance $540-560M.","Expects to approach quarterly EPS profitability and positive cash flow in 2H 2025; targets full-year EPS profitability and positive cash flow in 2026.","Plans 2025 NDA for ORLADEYO granules for children <12; two new pipeline programs to enter clinic (BCX17725, avoralstat).","2025 GAAP op ex guidance $485-495M (incl. ~$60M stock comp); non-GAAP op ex $425-435M."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-000155","json":"https://secwatch.observer/filing/0001171843-25-000155.json","markdown":"https://secwatch.observer/filing/0001171843-25-000155.md","text":"https://secwatch.observer/filing/0001171843-25-000155.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882796/000117184325000155/0001171843-25-000155-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882796/000117184325000155/f8k_011025.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T06:01:29.814937+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}